Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2017-05-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2017.4039PMID 28464141PMCID PMC5815013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs

  2016cited by this paper
• Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.

  2016cited by this paper
• Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.

  2016cited by this paper
• Antipsychotic Prescribing: Do Conflict of Interest Policies Make a Difference?

  2015cited by this paper
• Methods for evaluating changes in health care policy: the difference-in-differences approach.

  2014cited by this paper
• Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children.

  2014cited by this paper
• Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis

  2013cited by this paper
• Does Exposure to Conflict of Interest Policies in Psychiatry Residency Affect Antidepressant Prescribing?

  2013cited by this paper
• Can Access Limits on Sales Representatives to Physicians Affect Clinical Prescription Decisions? A Study of Recent Events With Diabetes and Lipid Drugs

  2012cited by this paper
• Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review

  2010cited by this paper
• Mortality among patients in VA hospitals in the first 2 years following ACGME resident duty hour reform.

  2007cited by this paper
• For sale: physicians' prescribing data.

  2006cited by this paper
• Solutions Manual and Supplementary Materials for Econometric Analysis of Cross Section and Panel Data

  2003cited by this paper
• Econometric Analysis of Cross Section and Panel Data, 2nd Edition

  2001cited by this paper

• Predicting Healthcare Provider Engagement in SMS Campaigns

  2025cites this paper
• The Genetic Data Market: Institutional Governance of Academic/Industry Research Partnerships for the Public Good

  2025cites this paper
• No margin, no mission? How emergency medical service crews attend to competing financial and social goals on 9‐1‐1 calls

  2025cites this paper
• Unsolicited Patient Complaints and Industry Payments for US Physicians

  2025cites this paper
• Networked narratives: Examining how Purdue Pharmaceuticals shaped public health policy and practice

  2025cites this paper
• Practice‐Level Clustering of Industry Payments to Clinicians

  2025cites this paper
• A Reply to: ‘Drug Survival of Biologics in Psoriasis: An Australian Multicentre Retrospective Study’

  2025cites this paper
• The Effect of Price Caps on Advertising to Physicians: Evidence from the 340b Drug Pricing Program

  2025cites this paper
• Factors affecting how soon the physicians try new drug: implication for pharmaceutical firms

  2025cites this paper
• No Free Lunch? Welfare Analysis of Firms Selling through Expert Intermediaries

  2024influential citation
• "Caught in Each Other’s Traps": Factors Perpetuating Incentive-Linked Prescribing Deals Between Physicians and the Pharmaceutical Industry

  2024cites this paper
• The Effect of Price Caps on Pharmaceutical Advertising: Evidence from the 340b Drug Pricing Program

  2024cites this paper
• Deep Professionalism: Charting a Path for Effective Conflict-of-Interest Management in Medicine

  2024cites this paper
• Doctors taking bribes from pharmaceutical companies is common and not substantially reduced by an educational intervention: a pragmatic randomised controlled trial in Pakistan

  2024cites this paper
• Nothing for Something: Marketing Cancer Drugs to Physicians Increases Prescribing Without Improving Mortality

  2024cites this paper
• The turbulent future of expertise and training markets

  2023cites this paper
• The paradox of disclosure: shifting policies from revealing to resolving conflicts of interest

  2023cites this paper
• The Role of Information in Pharmaceutical Advertising: Theory and Evidence

  2023influential citation
• Marketing of medicines in primary care: An analysis of direct marketing mailings and advertisements

  2023cites this paper
• Characterizing industry payments to US teaching hospitals and affiliated physicians: a cross-sectional analysis of the Open Payments datasets from 2016 to 2022.

  2023cites this paper
• Launching a new brand in the multi-brand portfolio: real world observational study evaluating mediating role of detailing priority and detailing time on physicians’ prescription behavior

  2023cites this paper
• Policies on doctors’ declaration of interests in medical organisations: a thematic analysis

  2023cites this paper
• Editorial: The evolution of my personal conflict of interest: I am part of an 'ineligible company'.

  2023cites this paper
• Interaction between physicians and the pharmaceutical industry: A scoping review for developing a policy brief

  2023cites this paper
• Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission.

  2022cites this paper
• Top-down and bottom-up approaches to low-value care

  2022cites this paper
• Bayesian Doublespeak∗

  2022cites this paper
• The Role of Physician Networks and Receipt of Opioid-Related Payments

  2022cites this paper
• Impact of the Affordable Care Act's Physician Payments Sunshine Act on branded statin prescribing

  2022cites this paper
• State-Level Estimates of the Prevalence of Parent-Reported ADHD Diagnosis and Treatment Among U.S. Children and Adolescents, 2016 to 2019

  2022cites this paper
• The Role of Social Norms on Direct-to-Physician Pharmaceutical Marketing Payment Acceptance

  2022cites this paper
• Acceptability and Efficacy of the SMARxT Media Literacy Education Program to Counter Pharmaceutical Marketing Influences among Medical Trainees

  2022cites this paper
• Effects and Trends in Opioid-Related Promotional Payments Between 2014 and 2019: a Panel Data Analysis Among Prescribers in Medicare Part D

  2022cites this paper
• Improving quality, affordability, and equity of multiple sclerosis care

  2021cites this paper
• Perceptions of the provision of drug information, pharmaceutical detailing and engagement with non-personal promotion at a large physicians network: a mixed-methods study

  2021cites this paper
• We Should Continue to Be Concerned About Conflicts of Interest in Academic Medicine

  2021cites this paper
• Medical Device Firm Payments To Physicians Exceed What Drug Companies Pay Physicians, Target Surgical Specialists.

  2021cites this paper
• Regulating Conflicts of Interest in Medicine Through Public Disclosure: Evidence from a Physician Payments Sunshine Law

  2021cites this paper
• Governing secondary research use of health data and specimens: the inequitable distribution of regulatory burden between federally funded and industry research

  2021cites this paper
• Why do medications with little or no efficacy continue to be prescribed in the management of patients with bipolar disorder?

  2021cites this paper
• Addressing Barriers to Reducing Prescribing and Implementing Deprescribing of Sedative-Hypnotics in Primary Care

  2021cites this paper
• Governing Secondary Research Use of Health Data and Specimens: The Inequitable Distribution of Regulatory Burden Between Federally-Funded and Industry Research

  2021cites this paper
• A pharmaceutical therapy recommender system enabling shared decision-making

  2021cites this paper
• Information shocks and pharmaceutical firms' marketing efforts: Evidence from the Chantix black box warning removal.

  2021cites this paper
• Missing the Forest for the Trees: Marketing Systems Approach to Pharmaceutical Industry Marketing Practices

  2021cites this paper
• The Professionalism Paradox: A Sense of Professionalism Increases Vulnerability to Conflicts of Interest

  2021cites this paper
• NBER WORKING PAPER SERIES DRUG DIFFUSION THROUGH PEER NETWORKS: THE INFLUENCE OF INDUSTRY PAYMENTS

  2020cites this paper
• Umbrella branding in pharmaceutical markets.

  2020cites this paper
• Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform

  2020cites this paper
• What Clinicians and Health Professions Students Should Learn About How Pharmaceutical Marketing Influences Opioid Prescribing and Patient Outcomes.

  2020cites this paper
• Physician’s interest to meet the sales rep and sample need: Implication to pharmaceutical detailing and sampling efforts

  2020cites this paper
• Evolving Communication with Healthcare Professionals in the Pharmaceutical Space: Current Trends and Future Perspectives

  2020cites this paper
• The Impact Of Academic Medical Center Policies Restricting Direct-To-Physician Marketing On Opioid Prescribing.

  2020cites this paper
• Research Ethics in IR: The Intersection Between Care and Progress.

  2020cites this paper
• Professional Ethics, Professionalization, and Regulation of Pharmaceutical Sales Representatives: Analyzing the Costa Rican Case

  2020cites this paper
• Saving face through preference signaling and obligation avoidance

  2020cites this paper
• Making Them Pay? Patient Ability to Pay and Care Disparities in Emergency Medical Services

  2020cites this paper
• Eliminating medication overload: A national action plan

  2020cites this paper
• Relación médico-industria y los conflictos de interés: aspectos históricos y normativos, impactos negativos y propuestas

  2019cites this paper
• Who cares about a label? The effect of pediatric labeling changes on prescription drug utilization

  2019cites this paper
• Selling and sales management

  2019cites this paper
• Conflict of interest disclosure as a reminder of professional norms: Clients first!

  2019influential citation
• Open data on industry payments to healthcare providers reveal potential hidden costs to the public

  2019cites this paper
• The Bionic Radiologist: avoiding blurry pictures and providing greater insights

  2019cites this paper
• Characteristics of Industry Payments to Ophthalmologists in the Open Payments Database.

  2019cites this paper
• An Implementation Guide to Promote Sleep and Reduce Sedative-Hypnotic Initiation for Noncritically Ill Inpatients.

  2019cites this paper
• Patient responses to physician disclosures of industry conflicts of interest: A randomized field experiment

  2019cites this paper
• Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses

  2019cites this paper
• Organizational Behavior and Human Decision Processes

  2019cites this paper
• Drug Diffusion Through Peer Networks: The Influence of Industry Payments.

  2019cites this paper
• Understanding Bias: A Look at Conflicts of Interest in IR.

  2019cites this paper
• Association of Mandatory Disclosure Policies and Laws With Physician-Industry Financial Relationships

  2019cites this paper
• Association between Opioid Prescribing in Medicare and Pharmaceutical Company Gifts by Physician Specialty

  2019cites this paper
• Organizational Behavior and Human Decision Processes

  2019cites this paper
• Examining gender differences in opioid, benzodiazepine, and antibiotic prescribing

  2019cites this paper
• Health decision making

  2018cites this paper
• Reduced Opioid Marketing Could Limit Prescribing Information for Physicians-Reply.

  2018cites this paper
• The Scope of Inclusion of Academic Conflict of Interest Policies

  2018cites this paper
• Extent of physician–pharmaceutical industry interactions in low- and middle-income countries: a systematic review

  2018cites this paper
• Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease. An Official American Thoracic Society Policy Statement

  2018cites this paper
• You Sponsor Mine , I Procure Yours : Pharmaceutical Sponsorships And Procurement in Public Hospitals

  2018cites this paper
• Evidence-Based Medicine and Conflict of Interest

  2018cites this paper
• Physician-Industry Interactions: Persuasion and Welfare

  2018influential citation
• Die Regulierbarkeit von unternehmerischer Korruption: Ein kriminologischer Forschungsüberblick

  2018cites this paper
• Possible Side Effects Investigating the connection between payments from pharmaceutical companies and the prescribing habits of physicians

  2018cites this paper
• Opioids: The Painful Public Health Reality

  2018cites this paper
• Conflicts of interest in infection prevention and control research: no smoke without fire. A narrative review

  2018cites this paper
• Are We for Sale? Awareness of Industry-Related Financial Conflicts of Interest in Radiation Oncology.

  2017cites this paper
• Shining Light on Conflicts of Interest

  2017cites this paper
• A Behavioral Blueprint for Improving Health Care Policy

  2017cites this paper
• Reconsidering Physician-Pharmaceutical Industry Relationships.

  2017cites this paper
• Tilburg University Umbrella Branding in Pharmaceutical Markets

  2017cites this paper
• Welfare Effects of Physician-industry Interactions: Evidence From Patent Expiration (PRELIMINARY — do not cite without permission)

  2017cites this paper
• Industrie-Einflüsse auf die Arzneimittelversorgung – mehr Unabhängigkeit ist möglich

  2017cites this paper
• The Scope of Inclusion of Academic Conflict of Interest Policies

  2017cites this paper
• Drug firms’ payments and physicians’ prescribing behavior in Medicare Part D

  2015cites this paper